MitoXcel™ Oncopeptides for Cancer
Perseus SENOLYTIX™ is an affiliated of SENOTHERAPEUTIX™
Perseus SENOLYTIX is developing novel MitoXcel™ oncopeptides to target cancer via this novel mechanism. In pre-clinical studies, our MitoXcel™ geropeptides and oncopeptides have been administered at escalating doses for over 16 weeks with no evidence of toxicity, opening the door for a potential safe and effective new class of cancer therapeutics.
